Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.
Publication/Presentation Date
6-2018
Published In/Presented At
Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.. JCO 36, 531-531(2018).
DOI:10.1200/JCO.2018.36.15_suppl.531Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS